Martínez-Bedoya D, Hernández-Vázquez AM, Rondón-Corrales T, Griñán-Ramirez T, Rodríguez-Zhurbenko N, Pupo-Meriño A, Cabrera-López L, Raymond-Pous J, Vázquez-Gallo AM, Pérez-Rodríguez R

Language: English
References: 10
Page: 2511-2513
PDF size: 274.22 Kb.

ABSTRACT

P3 monoclonal antibody (P3 mAb) recognizes gangliosides carrying N-glycolylated sialic acid, sulphated glycolipids and antigens expressed in human breast, lung and melanoma tumors. This mAb generates a strong anti-idiotypic IgG isotype response in the BALB / c syngeneic model, even when administered in the absence of adjuvants or carrier proteins. However, the role of different populations of B cells in the anti-idiotypic response, the ability of P3 mAb to activate CD8+ T cells despite being a self-molecule, or if it carried a regulatory idiopeptide with effect on activated CD8+ T cells were unknown. In this work, it was demonstrated that P3 mAb is capable of recognizing and activating populations of B-1a and B-2 lymphocytes, with the participation of CD8+ T cells, which in turn were able to activate cytotoxic CD8+ T cells in vitro. The immunization with the mAb P3 recovered in vivo the frequency of CD8+ T lymphocyte populations in mice subjected to different immunosuppressive regimens, and generated a specific CTL response by an idiopeptide exclusive of this antibody. The results suggested the possible existence of an alternative mechanism to induce the regulation of the immune response against self-antigens through idiotypic interactions under physiological conditions, which involves B and CD8+ T cells. This demonstrates the ability of P3 mAb to activate cytotoxic CD8+ T lymphocytes, with potential for therapeutic treatments in immunosuppressed patients. This work received the Annual Award of the Cuban Academy of Sciences for the year 2017.

REFERENCES

1. Vazquez AM, Alfonso M, Lanne B, Karlsson KA, Carr A, Barroso O, et al. Generation of a murine monoclonal antibody specific for N-glycolylneuraminic acid-containing gangliosides that also recognizes sulfated glycolipids. Hybridoma. 1995;14(6):551-6.

2. Moreno E, Lanne B, Vazquez AM, Kawashima I, Tai T, Fernandez LE, et al. Delineation of the epitope recognized by an antibody specific for N-glycolylneuraminic acid-containing gangliosides. Glycobiology. 1998;8(7):695-705.

3. Alfonso M, Diaz A, Hernandez AM, Perez A, Rodriguez E, Bitton R, et al. An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients. J Immunol. 2002;168(5):2523-9.

4. Neninger E, Diaz RM, de la Torre A, Rives R, Diaz A, Saurez G, et al. Active immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer: report of a phase I trial. Cancer Biol Ther. 2007;6(2):145-50.

5. Perez A, Mier ES, Vispo NS, Vazquez AM, Perez Rodriguez R. A monoclonal antibody against NeuGc-containing gangliosides contains a regulatory idiotope involved in the interaction with B and T cells. Mol Immunol. 2002;39(1-2):103-12.

6. Paul WE, Bona C. Regulatory idiotopes and immune networks: a hypothesis. Immunol Today. 1982;3(9):230-4.

7. Bona CA. Idiotype, internal image. In: Roitt IM, Delves PJ, editors. Encyclopedia of Immunology. London: Academic Press; 1992. p. 726-8.

8. Martinez D, Rodriguez N, Grinan T, Rondon T, Vazquez AM, Perez R, et al. P3 mAb: An immunogenic anti-NeuGcGM3 antibody with unusual immunoregulatory properties. Front Immunol. 2012;3:94.

9. Martínez D, Cabrera L, Hernández AM. P3, a monoclonal antibody capable to activate B-1a cells. Biotecnol Apl. 2016;33(2):2211-6.

10. Martinez D, Pupo A, Cabrera L, Raymond J, Holodick NE, Hernandez AM. B-CD8(+) T cell interactions in the antiidiotypic response against a self-antibody. J Immunol Res. 2017;2017:2860867.